Moderna Vaccine Shows Promise Against UK and South African COVID-19 Variants, Company Says

Moderna has announced that its Covid-19 vaccine was eliciting, in laboratory studies, the production of antibodies against the coronavirus variants identified in the United Kingdom and South Africa, which are beginning to spread in some countries. According to the press release from the American pharmaceutical laboratory, the administration of two doses of the vaccine will be sufficient to ensure protection against the emerging variants detected. On Wall Street, Moderna’s stock jumped up to 5.4% in pre-market trading after these announcements.

However, it indicates that it will test a booster dose of the vaccine against the variant identified in South Africa as part of pre-clinical trials in order to measure its effectiveness. It must be said that scientists are quite concerned about the emergence of the variants identified in the United Kingdom and South Africa, as they seem capable of modifying key functions of the virus.